|By JCN Newswire||
|July 2, 2014 06:46 AM EDT||
In addition to including the ingredients that have long been the foundation of the Chocola BB brand in Japan, such as vitamin B6, nicotinamide, royal jelly and taurine to support consumers' beauty and wellness, Chocola BB Royal Drink also specially contains collagen, L-carnitine, coix seed, polygonatum rhizome and goji berry to specifically address the needs of consumers in China. It also features an easy-to-drink pineapple flavor and is low in calories with approximately 9 kcal per bottle.
In recent years, the healthcare needs of consumers in China have been increasing in line with economic growth. Furthermore, beauty and healthcare related items have been very popular among women in China. In response to these trends, Eisai has launched Chocola BB Royal Drink as the first of its Chocola BB series of products in order to support consumers' beauty and wellness.
Chocola BB Royal Drink is sold through the internet in order to make the product readily accessible to women throughout the country. Following this new product launch to establish a foothold in China, Eisai plans to further introduce its over-the-counter (OTC) products into other countries in Asia.
Since its first product introduction in 1952, the Chocola BB series of products have been widely used by many customers in Japan, Taiwan and Hong Kong as a reliable healthcare brand. In Japan, Eisai has developed a wide range of products including mainstays such as Chocola BB Plus tablets (third-class OTC drug), Chocola BB Royal 2 (designated quasi-drug, drink), Chocola BB Sparkling (food with nutrient function claims, drink) and Bi Chocola (food with nutrient function claims) in response to the diverse needs of consumers.
By marketing the Chocola BB series of products, Eisai is committed to supporting the beauty and wellness of a wider group of consumers in the Asia region, including Japan and China.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Jul. 29, 2016 03:15 PM EDT Reads: 599
Jul. 29, 2016 03:00 PM EDT Reads: 368
Jul. 29, 2016 02:15 PM EDT Reads: 350
Jul. 29, 2016 02:00 PM EDT Reads: 1,200
Jul. 29, 2016 01:00 PM EDT Reads: 757
Jul. 29, 2016 01:00 PM EDT Reads: 699
Jul. 29, 2016 01:00 PM EDT Reads: 1,188
Jul. 29, 2016 01:00 PM EDT Reads: 2,093
Jul. 29, 2016 12:15 PM EDT Reads: 313
Jul. 29, 2016 12:00 PM EDT Reads: 1,830
Jul. 29, 2016 12:00 PM EDT Reads: 2,095
Jul. 29, 2016 11:30 AM EDT Reads: 1,251
Jul. 29, 2016 11:15 AM EDT Reads: 1,341
Jul. 29, 2016 11:15 AM EDT Reads: 678
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
Jul. 29, 2016 11:00 AM EDT Reads: 810